Developing Thermo-Stable Vaccines to Increase Access Around the World

Vaxess Technologies Awarded NSF and NIH Grants

6th Apr, 2015

CAMBRIDGE, Massachusetts—April 6th, 2015—Vaxess Technologies, Inc., an innovative life sciences company developing a novel silk protein-based vaccine technology, was awarded two separate Phase I Small Business Innovation Research Grants (SBIR) from the National Science Foundation (NSF) and the National Institute of Health (NIH). Funding totaling $360,000 will go toward the development of novel heat-stable rotavirus and polio vaccines and advancement of innovative vaccine presentation formats.

Vaxess Press Release
Fierce Vaccines

Announcing the 2014 ViE Awards Winners

1st Apr, 2014

VaccineNation and the World Vaccine Congress is proud to announce the winners of the 7th Annual ViE Awards.

Best Technological Development

Winner: Gates Foundation and intellectual Vaccines (Global Good) Cold chain technology
Highly Recommended: Vaxess Technologies (Novel silk protein-based vaccine stabilization technology)

Best Financing Deal

Winner: Hookipa Biotech and Boehringer Ingelheim Venture Fund, Takeda Ventures, Sofinnova Partners, Forbion Capital Partners and BioMedPartners – $27m Phase I
Highly Recommended: Vaxess Technologies and Norwich Ventures and Jeffrey C Walker –…

Harvard I-Lab Startup Vaxess Using Silk to Preserve Vaccines For Developing Countries

16th Sep, 2013

“You probably know that diseases like measles, mumps and rubella still afflict people in remote parts of the world, despite being eradicated long ago in developed countries. You might not know that one big reason isn’t a shortage of vaccines but rather a lack of refrigeration. Often, there’s just no way to keep immunizations cold enough, long enough to be effective.

Harvard Innovation Lab startup Vaxess Technologies is developing a way around the cold storage…

Copyright © 2015 Vaxess. All rights reserved.